CAS
IMUC

CTC Alternative Strategies’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

CTC Alternative Strategies’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-380
Closed -$29.5K – 247
2013
Q2 		$29.5K Buy
+380
New +$36.4K 0.01% 190

Other funds holding IMUC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CTC Alternative Strategies's IMUC Position: Q3 2013 in Review

CTC Alternative Strategies sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q3 2013, closing a stake of 380 shares — an estimated $29.5K sold.

CTC Alternative Strategies first reported a position in IMUC in Q2 2013 and held it in 1 quarter. The position peaked at $29.5K in Q2 2013. 37 funds tracked by Wall St. Rank hold IMUC as of Q3 2013.

  • CTC Alternative Strategies reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q3 2013 after selling out during the quarter.
  • CTC Alternative Strategies sold 380 ImmunoCellular Therapeutics, Ltd. shares in Q3 2013, an estimated $29.5K.
  • CTC Alternative Strategies first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 1 quarter.
  • CTC Alternative Strategies's ImmunoCellular Therapeutics, Ltd. position peaked at $29.5K in Q2 2013.
  • 37 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q3 2013.

Based on CTC Alternative Strategies's 13F filing for Q3 2013, filed 31 Oct 2013.